Pol Hans
University of Liège
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Pol Hans.
Cellular and Molecular Life Sciences | 1989
Joël Pincemail; M. Dupuis; C. Nasr; Pol Hans; M. Haag-Berrurier; R. Anton; Carol Deby
Ginkgo biloba extract is known to be efficient in diseases associated with free radical generation. The purpose of this work was to study, under in vitro conditions, the action ofGinkgo biloba extract (Gbe) against superoxide anion (
Anesthesiology | 2007
Koen Suy; Karl Morias; Guy Cammu; Pol Hans; Wilbert G. F. van Duijnhoven; Marten Heeringa; Ignace Demeyer
Neurosurgery | 1985
Jacques Born; Adelin Albert; Pol Hans; J Bonnal
O_{2^{\bar .} }
Anaesthesia | 2003
Christine Levaux; Vincent Bonhomme; Pierre-Yves Dewandre; Jean-François Brichant; Pol Hans
Neurosurgery | 1988
Germain Milbouw; J. D. Born; Didier Martin; Jacques Collignon; Pol Hans; Michel Reznik; J Bonnal
), which is directly or indirectly implicated in cell damage. Gbe appears to have both an
Anaesthesia | 2000
M. Mathy-Hartert; Ange Mouithys-Mickalad; S. Kohnen; G. Deby-Dupont; Maurice Lamy; Pol Hans
Journal of Neurosurgical Anesthesiology | 1994
Pol Hans; Vincent Bonhomme; Julien Collette; Adelin Albert; Gustave Moonen
O_{2^{\bar .} }
Journal of Neurosurgical Anesthesiology | 2000
Pol Hans; Vincent Collin; Vincent Bonhomme; François Damas; Jacques Born; Maurice Lamy
Journal of Neurosurgical Anesthesiology | 1997
Pol Hans; G. Deby-Dupont; C. Deby; F. Pieron; R. Verbesselt; Colette Franssen; Maurice Lamy
scavenging effect and also a superoxide dismutase activity. Its antiradical effect was demonstrated by low temperature electron spin resonance and in a non-enzymatic system (phenazine methosulfate-NADH), and its enzymatic activity was shown by polarographic determination.
BJA: British Journal of Anaesthesia | 2011
Vincent Bonhomme; Kimmo Uutela; Grégory Hans; Isabelle Maquoi; J. D. Born; Jean-François Brichant; Maurice Lamy; Pol Hans
Background:Sugammadex rapidly reverses rocuronium-induced neuromuscular block. This study explored the dose–response relation of sugammadex given as a reversal agent at reappearance of the second muscle twitch after rocuronium- and vecuronium-induced block. A secondary objective was to investigate the safety of single doses of sugammadex. Methods:In this two-center, phase II, dose-finding study, 80 patients (age ≥ 18 yr, American Society of Anesthesiologists physical status I or II, surgery ≥ 60 min requiring muscle relaxation for intubation) were randomly assigned to receive rocuronium (0.60 mg/kg) or vecuronium (0.10 mg/kg). Sugammadex or placebo was administered at reappearance of the second muscle twitch. The primary efficacy endpoint was time from starting sugammadex administration until recovery of the train-of-four ratio to 0.9. Results:Compared with placebo, sugammadex produced dose-dependent decreases in mean time to recovery for all train-of-four ratios in the rocuronium and vecuronium groups. The mean time for recovery of the train-of-four ratio to 0.9 in the rocuronium group was 31.8 min after placebo compared with 3.7 and 1.1 min after 0.5 and 4.0 mg/kg sugammadex, respectively. The mean time for recovery of the train-of-four ratio to 0.9 in the vecuronium group was 48.8 min after placebo, compared with 2.5 and 1.4 min after 1.0 and 8.0 mg/kg sugammadex, respectively. Sugammadex was well tolerated. Conclusion:Sugammadex rapidly reversed rocuronium- or vecuronium-induced neuromuscular block at reappearance of the second muscle twitch and was well tolerated. A dose–response relation was observed with sugammadex for reversal of both rocuronium- and vecuronium-induced neuromuscular block.